Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Herpes Zoster Vaccine Clear all
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

NCT05304351
View directory record Official record
Conditions
Herpes Zoster, Shingles
Interventions
Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
50 Years and older
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
14
States / cities
Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Immune Responses to Two Dose Varivax +/- MMR-II

NCT00258726
View directory record Official record
Conditions
Measles, Mumps, Rubella, Varicella
Interventions
MMR-II, Pro-Quad, Varivax
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 12 Months
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 23, 2026, 10:13 AM EDT
Terminated No phase listed Observational

Solid Organ Transplant SHINGRIX

NCT03993717
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
SHINGRIX
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Shingles Prevention Study

NCT00007501
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Varicella-zoster vaccine, Placebo
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
38,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

ZOSTAVAX® in Renal Transplant Patients

NCT01137669
View directory record Official record
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents

NCT01262300
View directory record Official record
Conditions
Immunosenescence, Shingles
Interventions
Varicella Zoster Virus Vaccine (Zostavax)
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

NCT01519570
View directory record Official record
Conditions
Herpes Zoster Disease
Interventions
An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Other
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
2,589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View directory record Official record
Conditions
Varicella, Rubella, Mumps, Measles
Interventions
Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 14 Months
Enrollment
1,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
141
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

NCT04540081
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions
Epic Healthy Planet Population Health Module
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vaccination Education Through Pharmacists and Senior Centers (VEPSC)

NCT03239665
View directory record Official record
Conditions
Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
Interventions
Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

NCT03798691
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACTIVATE in Public Housing

NCT06075732
View directory record Official record
Conditions
Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
Interventions
Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT05580458
View directory record Official record
Conditions
Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jul 23, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MMR and Varicella Vaccine in Premature Infants

NCT00156559
View directory record Official record
Conditions
Chickenpox, Rubella, Rubeola, Mumps
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Months to 16 Months
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Jul 23, 2026, 10:13 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
View directory record Official record
Conditions
Chickenpox
Interventions
Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

NCT06693895
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 10:13 AM EDT
Recruiting Phase 4 Interventional

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NCT05559671
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 23, 2026, 10:13 AM EDT